Targeting cancer with PI3K pathway inhibitors: Who to aim at?

Kathryn M. Kinross, Karen E Sheppard, Richard B. Pearson, Wayne A. Phillips

Research output: Contribution to journalArticleOtherpeer-review

2 Citations (Scopus)


Breast and gynecological (ovarian, endometrial and cervical) cancers commonly harbor mutations activating the PI3K pathway, including PIK3CA mutation/amplification, PTEN loss or HER2 amplification. Insight from the successful development of many targeted cancer therapeutics suggests that these tumor types with a high prevalence of mutations in the PI3K pathway would be ideal candidates for therapy with inhibitors of that pathway. This was indeed the case with imatinib to target Bcr-Abl positive CML patients and cKIT mutant GIST tumors; vemurafenib to target B-RAFV600E melanoma; trastuzumab to target HER2 positive breast cancer; and crizotinib to target EML4-ALK positive lung tumors.

Original languageEnglish
Pages (from-to)119-121
Number of pages3
JournalTranslational Cancer Research
Issue number2
Publication statusPublished - 1 Aug 2012

Cite this